Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage

General Hospital of Shenyang Military Region1,682 enrolled

Overview

Terlipressin and somatostatin/octreotide are the first-line choices for the treatment of acute variceal bleeding in liver cirrhosis. Acute kidney injury can develop in patients presenting with acute variceal bleeding. On the other hand, evidence suggests that terlipressin can reverse hepatorenal syndrome. It has been hypothesized that terlipressin can protect the renal function in cirrhotic patients with acute variceal bleeding, except for control of bleeding.

Study Type

OBSERVATIONAL

Enrollment

1,682

Conditions

Variceal Hemorrhage Cirrhosis, Liver Kidney Injury

Interventions

TerlipressinDRUG

Continuous or intermittent intravenous infusion of terlipressin was given.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1. Cirrhotic patients who were admitted between January 2010 and December 2018. 2. A diagnosis of acute gastrointestinal bleeding. 3. Patients who received terlipressin or somatostatin/octreotide. 4. Age or sex was not limited. 5. Use of endoscopy was not limited. 6. Comorbidity was not limited. 7. Malignancy was not limited. Exclusion Criteria: 1. Renal parenchymal diseases. 2. Absence of baseline serum creatinine. 3. Absence of serum creatinine 3-5 days after terlipressin or somatostatin/octreotide. 4. Duration of terlipressin or somatostatin/octreotide was less 3 days. 5. Patients who underwent transjugular intrahepatic portosystemic shunt. 6. Patients who underwent surgical shunt, splenectomy with or without devascularization, or liver transplantation.

Locations (14)

Center for Liver Cirrhosis, The Fifth Medical Center of PLA General Hospital

Beijing, Beijing Municipality, China

Difficult & Complicated Liver Diseases and Artificial Liver Center, Beijing YouAn Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Liver Research Center, The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China

Department of Hepatobiliary Disease, 900 Hospital of the Joint Logistics Team (formerly called Fuzhou General Hospital)

Fuzhou, Fujian, China

Department of Gastroenterology, The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

Department of Gastroenterology, The First Affiliated Hospital of China Medical University

Shenyang, Liaoning, China

Department of Critical Care Medicine, The Sixth People's Hospital of Shenyang

Shenyang, Liaoning, China

Department of Gastroenterology, Air Force Hospital of Northern Theater Command

Shenyang, Liaoning, China

Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area)

Shenyang, Liaoning, China

Department of Gastroenterology, Xi'an Central Hospital

Xi'an, Shaanxi, China

...and 4 more locations

Outcomes

Primary Outcomes

Incidence of ICA-AKI and kidney function damage in cirrhotic patients with acute gastrointestinal bleeding

ICA-AKI and kidney function damage

Time frame: Through study completion, an average of 1-2 weeks

Effect of ICA-AKI and kidney function damage on in-hospital mortality of cirrhotic patients with acute gastrointestinal bleeding

In-hospital mortality

Time frame: Through study completion, an average of 1-2 weeks

Effect of terlipressin on the in-hospital mortality of cirrhotic patients with acute gastrointestinal bleeding with ICA-AKI and kidney function damage

In-hospital mortality associated with ICA-AKI and kidney function damage

Time frame: Through study completion, an average of 1-2 weeks